Health technology and insulin manufacturers are committed to supporting WHO demands

Share This Post

  • The WHO underscores the worrying global access to insulin and diabetes care, pointing to high costs, a dearth of human insulin, and the market’s domination. Few manufacturers, he notes, are doing this, and the medical system is susceptible. It is the main obstacle to accessibility for everybody.

The researchers who developed insulin one hundred years ago chose not to profit from their discovery and instead sold the patent for a meager $1. The late Tedros Adhanom Ghebreyesus. Regrettably, this act of solidarity The WHO is working with nations and manufacturers to close those gaps and make access to this life-saving medication a requirement. It has been replaced by multi-billion dollar transactions that have produced enormous access gaps. It is becoming more inclusive.

For the 9 million patients with type 1 diabetes, insulin is the cornerstone of diabetes therapy, changing a fatal condition into one that is controllable. Insulin is necessary for the more than 60 million people with type 2 diabetes to lower their risk of renal failure, blindness, and amputation.

However, one in every two individuals with type 2 diabetes who require insulin do not receive it. In low- and middle-income nations, diabetes is becoming more prevalent, but insulin consumption there has not kept pace with the spread of the condition. The paper points out that even though three out of four persons with type 2 diabetes reside outside of North America and Europe, they only generate less than 40% of the money from the sale of insulin.

Lower-income nations are bearing an unsustainable financial burden as a result of the worldwide market shift away from human insulin, which can be produced at a reasonable price, and toward the more expensive analogues (synthetic insulins). Human insulin is generally just as effective as analogues, although analogues cost at least 1.5 times as much as human insulin and, in certain countries, three times as much;

The report Keeping the 100-year-old Promise: Making Insulin Access Universal, released today to mark the 100th anniversary of the discovery of insulin, identifies the following as the primary reasons for the insulin access gaps around the world:

More than 90% of the insulin industry is controlled by three multinational corporations, leaving little room for smaller businesses to compete for insulin sales;

Access to insulin and associated devices, such as monitoring and delivery devices, is hampered in all nations by subpar regulation and policies, including subpar pharmaceutical pricing approaches, weak procurement and supply chain management, insufficient financing to meet demand, and general subpar governance;

Lack of service integration at the primary care level, insufficient capacity for treating diabetes and ensuring supply continuity, and inadequate infrastructure for information management, supply management, and local production of insulin are all problems that lower-income countries frequently face; Research is focused on affluent markets, ignoring the public health requirements of low- and middle-income nations, which bear 80% of the burden of diabetes.

Related Posts

There are rumors of another Netflix spin-off for The Witcher

Netflix’s The Witcher is reportedly gearing up for another...

Street Fighter 6 could arrive sooner than expected

Street Fighter fans received some news this week about...

Virginia General Assembly questions charity game

Virginia’s House approved a bill authorizing gambling for charity...

Former BioWare developer reveals hilarious alternate ending to Mass Effect 3

A rather amusing alternate ending for Mass Effect 3...

Preparations are underway for the first “Border Games”

Giving one of the keynotes at the historic revival...

It won’t be long before Modern Warfare 2 is free to play

Call of Duty: Modern Warfare 2 will soon be...